DigitalEd Announces Growth Investment From PSG
Today, DigitalEd announces a growth investment from PSG; a leading growth equity firm partnering with middle-market software and technology-enabled services companies. DigitalEd provides a SaaS-based digital learning platform called Möbius, focusing on science, technology, engineering and mathematics (STEM) education. PSG is DigitalEd’s sole outside investor. Financial terms were not disclosed.
DigitalEd was founded in 2018 with a simple and resonant mission - to shape the world through digital learning. DigitalEd provides individual learning, in a shared world, allowing students to acquire knowledge at a guided, self-defined pace. DigitalEd currently supports over 300 educational institutions worldwide, administering over 20 million tests and assignments, supporting online learning for world-class universities, institutes of technology, and community colleges.
Möbius is an innovative and comprehensive platform for STEM education. The platform is designed to reduce the time educators need to spend on administrative tasks, traditionally required for course preparation and grading, allowing them to maximize time spent teaching and interacting with students. The platform focuses on student success by providing educators with high-quality course content created by STEM curriculum experts. Möbius can deliver coursework and monitor student performance with analytics. For students, Möbius provides an interactive digital learning environment that can be accessed anytime, anywhere, providing sophisticated automatic marking and immediate, focused student feedback.
“We are extremely proud of the ongoing adoption of Möbius, and how it has allowed online education to enhance and improve traditional education,” said Jim Cooper, Founder and CEO of DigitalEd. “We believe the PSG team understands and is committed to our founding vision. In our view, they are a perfect partner for DigitalEd, as we seek to continue to expand the Möbius platform to empower educators by both measuring and improving the learning experience.”
“We believe DigitalEd has a robust and highly scalable platform which is uniquely positioned for growth amid the rising demand for both e-learning tools and STEM education,” said Chris Andrews, Principal at PSG. “We look forward to working alongside Jim, Christina and the rest of DigitalEd’s talented team in an effort to accelerate the company’s growth through product innovation, strategic go-to-market initiatives and continued focus on user experience.”
“Everything we do at DigitalEd is grounded in optimizing the experiences and successes of students,” said Christina Perdikoulias, President of DigitalEd. “We are excited to partner with PSG and continue our commitment to providing high-quality, individualized and accessible education at scale.”
Stikeman Elliot LLP and Weil, Gotshal & Manges LLP served as legal advisors to PSG. Gowlings WLG, Grant Thornton LLP and Tyton Partners served as advisors to DigitalEd.
About DigitalEd
DigitalEd is a cloud-based software company devoted to improving student educational success. At DigitalEd, we have used our beliefs, values and core pillars of software development to build the Möbius platform; an innovative and comprehensive learning platform for Science, Technology, Engineering and Mathematics.To learn more about DigitalEd, visit: www.digitaled.com
About PSG
PSG is a growth equity firm that partners with middle-market software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 80 companies and facilitated over 325 add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology and a firm commitment to collaborating with management teams. Founded in 2014, PSG operates out of offices in Boston, Kansas City and London. To learn more about PSG, visit www.psgequity.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210803005210/en/
Contact information
Media
DigitalEd
Siobhan Paul
spaul@digitaled.com
PSG
Jackie Schofield
Prosek Partners (on behalf of PSG)
jschofield@prosek.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DXC Technology Completes Refinancing Actions24.9.2021 22:30:00 CEST | Press release
DXC Technology Company (NYSE: DXC) (“DXC”) today announced the completion of its refinancing. DXC previously completed the offering of €1.35 billion Senior Notes priced on September 2, 2021 and $1.35 billion Senior Notes priced on September 7, 2021. DXC completed redemption of $2.5 billion principal of (i) EUR term loan in the amount of €400 million due FY23 and FY24, (ii) $500 million 4.25% Senior notes due FY25, (iii) £250 million 2.75% Senior notes due FY25, (iv) $467 million 4.125% Senior notes due FY26, (v) $500 million 4.75% Senior notes due FY28, and (vi) $234 million Senior notes due FY30. The applicable make whole premium for these redemptions was $300 million and accrued and unpaid interest was $40 million. Ken Sharp, Chief Financial Officer, DXC commented: “Our opportunistic debt refinancing of $2.5 billion of our high coupon debt further solidifies our financial foundation by extending our debt maturities, lowering our maturity towers and reducing our ongoing interest expen
Schlumberger Announces Third-Quarter 2021 Results Conference Call24.9.2021 16:00:00 CEST | Press release
Schlumberger Limited (NYSE:SLB) will hold a conference call on October 22, 2021 to discuss the results for the third quarter ending September 30, 2021. The conference call is scheduled to begin at 9:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 8858313. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until November 22, 2021, and can be accessed by dialing +1 (866) 207-1041 within North America or +1 (402
Tradeweb Successfully Completes its First Southbound Bond Connect Transactions24.9.2021 14:07:00 CEST | Press release
Tradeweb Markets Inc. (Nasdaq: TW), a leading global operator of electronic marketplaces for rates, credit, equities and money markets, today announced it has completed its first Southbound Bond Connect transactions via the trading link between Tradeweb and China Foreign Exchange Trade System (CFETS). “Southbound Bond Connect is the latest evolutionary step for China’s financial market, providing domestic investors with more flexibility and choice when trading offshore bonds,” said Lee Olesky, CEO of Tradeweb Markets. “Together with CFETS, our goal is to better meet onshore investors’ demand for streamlined access to global investment. We will continue to focus on further enhancing the trading link by deploying new innovative trading functionality, just as we did with the Northbound leg of Bond Connect.” Southbound Bond Connect facilitates fixed income portfolio diversification for institutional investors in China. Tradeweb collaborates closely with CFETS to create a uniform trading ex
H.I.G. Capital Acquires Aspire Pharma24.9.2021 14:05:00 CEST | Press release
H.I.G. Capital, LLC (“H.I.G.”), a leading global alternative investment firm with $45 billion of equity capital under management, is pleased to announce that one of its affiliates has acquired Aspire Pharma Limited (“Aspire” or the “Company”), a leading UK provider of niche generic and branded specialty pharmaceuticals, alongside its founder Graham Fraser-Pye. The financial terms of the transaction have not been disclosed. Aspire licenses and develops niche generic and specialty pharmaceutical products that offer innovative formulations, value for money for payors, and reliable supply arrangements in markets that are often underserved. The business holds leadership positions in urology, ophthalmology, CNS and dermatology, with a highly diversified portfolio of more than 250 products across multiple categories, including branded specialty products and unbranded niche generics. H.I.G., together with the management team, aims to continue Aspire’s strong track record of organic growth and
Swappable Announces Partnership with Esports T1's Dota 2 Team24.9.2021 13:34:00 CEST | Press release
Swappable, an NFT (Non-Fungible Token) interface for high-profile and exclusive digital collectibles, has announced its partnership with T1's Dota 2 team, the popular esports team for the upcoming International 10 - Dota 2 World Championship in Bucharest, Romania. T1 is not just an esports team but a pop culture phenomenon with millions of fans worldwide. The team embodies a blend of lifestyle, creativity and attitude, fresh from the source of Seoul & LA. As part of the collaboration, T1 will auction their first-ever NFTs (digital collectibles) on Swappable for T1’s Genesis Collection. With the first auction starting Friday September 24th, T1 will release a series of NFTs each possessing utility features such as special access to T1's Dota 2 team players and more. Visit Swappable for more information. “We are excited to partner with a leading organization in the esports industry. It is also a chance for T1 fans to pick the very first digital collectibles ever created by this legendary
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-1924.9.2021 13:00:00 CEST | Press release
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its prespecified interim analysis data review of the safety and efficacy of SAB-185 in the Phase 2 portion of the ACTIV-2 trial and has recommended advancement to Phase 3. SAB-185 is a fully-human, specifically-targeted, broadly-neutralizing polyclonal antibody therapeutic candidate for the treatment of non-hospitalized patients with mild to moderate COVID-19. It is being assessed in the ACTIV-2 trial funded and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH) in collaboration with the AIDS Clinical Trials Group. SAB-185 is advancing to the Phase 3 trial based on meeting pre-defined graduation crite
NTHU Researchers Develop Ultrasonic Vortex Thrombolytic Device24.9.2021 11:00:00 CEST | Press release
As COVID-19 vaccination has raised the issue of thrombosis, Dr. Chih-Kuang Yeh, Distinguished Professor of the Department of Biomedical Engineering and Environmental Sciences, has led a research team to developed the world's first ultrasonic vortex thrombolytic device and to treat thrombosis quickly and safely. The research has been published in Proceedings of the National Academy of Sciences (PNAS) in 2021. Moreover, U.S. and EU patents are granted, with more applications on the way. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210924005015/en/ (Photo: National Tsing Hua University) The device is developed to solve two common thrombosis called pulmonary embolism (PE) and deep vein thrombosis (DVT), which have global prevalence of 10 million new cases annually. DVT is the main cause of PE, and PE can cause heart failure and has mortality rate up to 65%. Professor Yeh explained that the current treatment options includes dr